Overview

Malaysia Stop Tyrosine Kinase Inhibitor Trial

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

To compare administration of peginterferon-α-2a for 1 year versus observation after stopping tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) patients with deep MR ≥ 2 years.

Phase:

Phase 3

Details

Lead Sponsor:

Ministry of Health, Malaysia

Treatments:

Peginterferon alfa-2a